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Abstract: This transversal study was suggested in order to estimate the nationwide 
  seroprevalences of HIV infection and hepatitis B among 495 pregnant women in Niger in 2008. 
The study detected anti-HIV antibodies with Genscreen® Plus HIV Ag/Ab Ultra Kit (Bio-Rad; 
Hercules, CA), Vironostika® HIV Uni-Form II Ag/Ab (bioMérieux; Marcy-l’Etoile, France), 
and ImmunoComb® II HIV 1 and 2 BiSpot (Orgenics; Yavne, Israel). HBsAg was detected 
by Monolisa® HBsAg Ultra (Bio-Rad) and ImmunoComb® II HBsAg (Orgenics). The rates 
obtained were 2.02% (95% confidence intervals (CI): 1.03%–3.81%) and 16.16% (95% CI: 
13.09%–19.77%), respectively. There were no significant variations according to environ-
ment, region, age, marital status, educational level, antecedent of surgery and transfusion. But 
these data need a large sample, and periodic updates for a better planning of activities in the 
framework of a national reproductive health program, including prevention of mother-to-child 
HIV transmission.
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Introduction
Human immunodeficiency virus (HIV) infection and hepatitis are common vertically 
communicable diseases, with relatively high prevalence in sub-Saharan Africa. The 
Joint United Nations Programme on HIV/AIDS (UNAIDS) reported 22.4 million 
infected persons in this area, representing 67% of the total global cases in 2008.1 
Over 2 billion people have evidence of previous hepatitis B virus (HBV) infection 
and 350 million have become chronic carriers of the virus with 60 million of them 
residing in Africa.2 The correlation between chronic HBV infection and hepatocellular 
carcinoma (HCC) has been proven both experimentally and epidemiologically.3,4
For the two diseases, few reported data are available from Niger, a country located 
between Algeria and Nigeria, with 1.267 million square kilometers for only 15 million 
inhabitants. The main objective of this study was to generate nationwide data to aid the 
planning of appropriate activities for the prevention of mother-to-child HIV transmis-
sion, and national reproductive health programs.
Material and methods
Sampling method
The size of the representative sample was estimated in agreement with statistical 
constraints, and taking account with eventual refusal cases, insufficiently impreg-
nated filter paper, and those with missing information. Pregnant women attending 
antenatal clinics were sourced from mother and infant health services, chosen for their 
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high   frequentation, in each region. Those who declined to 
  participate in the study were not replaced.
Data collection
Every eligible woman was asked to answer questions about 
demographic data, education level, and antecedent of sur-
gery or blood transfusion. Standardized questionnaires were 
filled in by the investigators (midwifes). A code number was 
used to identify study participants. After finger pricking 
with sterile disposable safety lancets, blood was collected 
on calibrated spots of filter paper (Serobuvard® LDA22; 
  Ploufragan, France). The blood spots were left to dry at 
ambient temperature; then the dried blood spots (DBS) were 
placed in paper envelopes for transport to a laboratory by the 
supervisors of the survey.
Laboratory method
Briefly, after overnight incubation of the DBS, the eluates 
were used for the screening of the different markers. For 
HIV infection, the study used Genscreen® Plus HIV Ag/Ab 
Ultra Kit (Bio-Rad; Hercules, CA) first. Negative speci-
mens were then definitely considered as corresponding to 
noninfected individuals. Positive specimens were tested 
with   Vironostika® HIV Uni-Form II Ag/Ab (bioMérieux; 
Marcy-l’Etoile, France); negative results were considered 
as definitive while positive results were later tested with 
ImmunoComb® II HIV 1 and 2 BiSpot (Orgenics; Yavne, 
Israel) to discriminate HIV-1 and HIV-2. HBsAg was detected 
by Monolisa® HBsAg Ultra (Bio-Rad) and ImmunoComb® 
II HBsAg (Orgenics).
Data analysis
Data analysis was performed with Epi Info™ 6 software 
(Centers for Disease Control and Prevention (CDC); Atlanta, 
GA). Confidence intervals (CI) were calculated by using the 
Fleiss quadratic method.5 Pearson’s X2 and Fisher’s exact 
tests were used whenever appropriate (a P-value ,0.05 was 
considered significant).
Ethical aspects
Informed oral consent was obtained from study participants 
after an explanation of the aims and methods of the survey 
that included unequivocal reference to HIV testing and the 
assurance that no individual results could be generated by the 
study design. Collected data were anonymous and unlinked. 
Women were strongly encouraged to accept the routine 
antenatal HIV infection and syphilis screening.
Results
Five hundred and eight pregnant women were asked to 
  participate, of which, 506 accepted and were tested; the refusal 
rate was 0.39%. Eleven women were not tested because 
of insufficiently impregnated filter papers and/or missing 
  information. The final size of the sample was 495 women.
The overall seroprevalence was 2.02% (95% CI: 1.03%–
3.81%) for HIV and 16.16% (95% CI: 13.09%–19.77%) 
for hepatitis B. Three cases of coinfection HIV–HBV were 
found. All HIV strains were type 1.
As presented in Tables 1 and 2, there were no significant 
variations of HIV infection rate according to environment 
(P = 0.814); region (P = 0.619); age (P = 0.907); marital 
status (P = 0.780); or educational level (P = 0.738). Also, 
  variations were not significant for HBV according to 
environment (P = 0.616); region (P = 0.999); age (P = 0.997); 
marital status (P = 0.618); educational level (P = 0.584);   history 
surgery (P = 0.703); or blood transfusion (P = 0.953).
Discussion
HIV seroprevalence in the general population of Niger was 
0.9% in 2002 and 0.7% in 2006.6,7 Two previous HIV sero-
surveys among pregnant women were conducted the same 
Table 1   Seroprevalence  of  the  two  markers  according  to 
environment, region, and age of 495 pregnant women
Feature Number HIV HBsAg
+ Prevalence + Prevalence
Environment
Urban 241 5 2.07% 42 17.01%
Rural 254 5 1.97% 38 15.35%
P value 0.814 0.616
Region
Agadez 68 1 1.47% 11 16.17%
Diffa 26 0 0% 4 15.38%
Dosso 67 2 2.98% 10 14.93%
Maradi 61 1 1.64% 9 14.75%
Niamey 73 0 0% 12 16.43%
Tahoua 68 2 2.94% 12 17.65%
Tillaberi 61 0 0% 10 16.39%
Zinder 71 4 5.63% 12 16.90%
P value 0.619 0.999
Age (years)
15–19 84 3 3.57% 13 15.48%
20–24 147 3 2.04% 24 16.33%
25–29 125 3 2.4% 20 16%
30–34 54 1 1.85% 8 14.81%
35–39 39 0 0% 7 17.95%
40–44 44 0 0% 8 18.18%
45–49 2 0 0% 0 0%
P value 0.907 0.997
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years, in three administrative regions within the UNFPA 
program, and one site by region. The overall rates reported 
were 0.96% (95% CI: 0.5%–1.7%) and 1.2% (95% CI: 
0.7%–2.1%), respectively.8 The present study used a sub-
sample from all eight regions of Niger for a better estimation 
of HIV seroprevalence among pregnant women in 2008. The 
rate of 2.02% (95% CI: 1.03%–3.81%) was not significantly 
different from the 2002 and 2006 rates (P = 0.196). HIV-1 was 
responsible for all cases of HIV infection in this study; these 
data are in agreement with the general decreasing of HIV-2 
prevalences in Niger and other West African countries.9,10 
These updated data provided by the study made a useful 
contribution to the planning of HIV-vertical transmission 
prevention in the recent HIV/AIDS proposition to the Round 
10 Global Fund Against AIDS, Tuberculosis and Malaria. 
However, the sample size of this study was relatively small 
for testing factors potentially relevant to HIV infection among 
antenatal clinic attendees in Niger.
For hepatitis B screening, HBsAg is still the main 
marker, despite some false–negative results caused by 
the rare variation in the antigenic determinant a, observed 
in occult hepatitis.11,12 The relatively high rate of HBsAg 
carriage among pregnant women is in agreement with the 
  well-established hyperendemicity of HBV in sub-Saharan 
Africa. Previous studies reported similar levels of this marker 
in various groups in Niger: 17.6% among students in 1985 
and HIV positive people in 2007; 14.46% among blood 
donors in 2007.13–15 Nevertheless, no concrete measure of 
control has been undertaken for this vaccine-preventable 
disease, until September 2008 when hepatitis B vaccine 
was used in a routine vaccination program. Also, HBsAg 
detection is required in the package of antenatal biological 
screenings. HBV vertical transmission can be avoided by 
vaccinating newborns as early as possible, preferably before 
departure from the maternity hospital.
In conclusion, this study demonstrated that the HIV preva-
lence rate was enough to declare a HIV generalized epidemic 
in Niger, but a large scale study for data confirmation and 
for testing factors relevant to HIV infection among pregnant 
women is needed. For hepatitis B, these data clearly showed the 
pertinence and the necessity of considering HBsAg systematic 
screening as an important disease control strategy. This is a 
challenge for the national reproductive health program.
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